Epidemiology of invasive meningococcal disease in the Netherlands, 1960-2012: An analysis of national surveillance data

The Lancet Infectious Diseases

Volumn 14, Issue 9, 2014, Pages 805-812

  Bijlsma, Merijn W ^a   Bekker, Vincent ^a   Brouwer, Matthijs C ^a   Spanjaard, Lodewijk ^a   van de Beek, Diederik ^a   van der Ende, Arie ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; PENICILLIN DERIVATIVE;

ARTICLE; DISEASE SURVEILLANCE; HUMAN; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NETHERLANDS; NONHUMAN; PENICILLIN RESISTANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; MENINGOCOCCAL INFECTIONS; MIDDLE AGED; NETHERLANDS; POPULATION SURVEILLANCE; TIME FACTORS; VACCINATION;

EID: 84906934999     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70806-0     Document Type: Article

References (35)

1. Stephens DS, Greenwood B, Brandtzaeg P Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007, 369:2196-2210.
2. Harrison LH, Trotter CL, Ramsay ME Global epidemiology of meningococcal disease. Vaccine 2009, 27(suppl 2):B51-B63.
3. Harrison OB, Claus H, Jiang Y, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis 2013, 19:566-573.
4. Frasch CE, Chapman SS Classification of Neisseria meningitidis group B into distinct serotypes. I. Serological typing by a microbactericidal method. Infect Immun 1972, 5:98-102.
5. Jolley KA, Brehony C, Maiden MC Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol Rev 2007, 31:89-96.
6. Maiden MC, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 1998, 95:3140-3145.
7. McIntyre PB, O'Brien KL, Greenwood B, van de Beek D Effect of vaccines on bacterial meningitis worldwide. Lancet 2012, 380:1703-1711.
8. Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009, 27(suppl 2):B3-12.
9. Kaaijk P, van Straaten I, van de Waterbeemd B, et al. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. Vaccine 2013, 31:1065-1071.
10. Delbos V, Lemee L, Benichou J, et al. Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage. Vaccine 2013, 31:4416-4420.
11. Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013, 381:825-835.
12. Vogel U, Taha MK, Vazquez JA, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013, 13:416-425.
13. Meningococcal B vaccine: JCVI position statement (accessed March 27, 2014). https://www.gov.uk/government/publications/meningococcal-b-vaccine-jcvi-position-statement.
14. Holst J, Nokleby H, Bettinger JA Considerations for controlling invasive meningococcal disease in high income countries. Vaccine 2012, 30(suppl 2):B57-B62.
15. Ouchterlony O Antigen-antibody reactions in gels. Acta Pathol Microbiol Scand 1949, 26:507-515.
16. Poolman JT, Abdillahi H Outer membrane protein serosubtyping of Neisseria meningitidis. Eur J Clin Microbiol Infect Dis 1988, 7:291-292.
17. Scholten RJ, Bijlmer HA, Poolman JT, et al. Meningococcal disease in The Netherlands, 1958-1990: a steady increase in the incidence since 1982 partially caused by new serotypes and subtypes of Neisseria meningitidis. Clin Infect Dis 1993, 16:237-246.
18. Bambini S, Piet J, Muzzi A, et al. An analysis of the sequence variability of meningococcal fHbp, NadA and NHBA over a 50-year period in the Netherlands. PLoS One 2013, 8:e65043.
19. Access to StatLine: make your own tables Central Bureau of Statistics, (accessed Aug 1, 2013). http://www.cbs.nl/en-GB/menu/cijfers/statline/zelf-tabellen-maken/default.htm?Languageswitch=on.
20. Severin WP, Ruys AC, Bijkerk H, Butter MN The epidemiology of meningococcal meningitis in the Netherlands in recent years, with special reference to the epidemic of 1966. Zentralbl Bakteriol Orig 1969, 210:364-370.
21. de Greeff SC, de Melker HE, Spanjaard L, van den Hof S, Dankert J [The first effect of the national vaccination campaign against meningococcal-C disease: a rapid and sharp decrease in the number of patients]. Ned Tijdschr Geneeskd 2003, 147:1132-1135.
22. Trotter CL, Ramsay ME Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 2007, 31:101-107.
23. Jafri RZ, Ali A, Messonnier NE, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr 2013, 11:17.
24. Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012, 379:617-624.
25. Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol 2011, 18:483-486.
26. Broker M, Jacobsson S, DeTora L, Pace D, Taha MK Increase of meningococcal serogroup Y cases in Europe: a reason for concern?. Hum Vaccin Immunother 2012, 8:685-688.
27. Taha MK, Achtman M, Alonso JM, et al. Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet 2000, 356:2159.
28. Mayer LW, Reeves MW, Al-Hamdan N, et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J Infect Dis 2002, 185:1596-1605.
29. Cockerill FR, Wilson JW, Vetter EA, et al. Optimal testing parameters for blood cultures. Clin Infect Dis 2004, 38:1724-1730.
30. Peltola H, Kataja JM, Makela PH Shift in the age-distribution of meningococcal disease as predictor of an epidemic?. Lancet 1982, 2:595-597.
31. Christensen H, May M, Bowen L, Hickman M, Trotter CL Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10:853-861.
32. Kriz P Surveillance of invasive meningococcal disease in the Czech Republic. Euro Surveill 2004, 9:37-39.
33. Lind I, Berthelsen L Epidemiology of meningococcal disease in Denmark 1974-1999: contribution of the laboratory surveillance system. Epidemiol Infect 2005, 133:205-215.
34. Gray SJ, Trotter CL, Ramsay ME, et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006, 55:887-896.
35. Martin NG, Sadarangani M, Pollard AJ, Goldacre MJ Hospital admission rates for meningitis and septicaemia caused by Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae in children in England over five decades: a population-based observational study. Lancet Infect Dis 2014, 14:397-405.